SavedAdd your journal

Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 2

Gene therapy, Stem Cell Treatment and Retinal Implant in Dry-Form (Non-Neovascular) Age Related Macular Degeneration

Kuru Tip (Non-Neovasküler) Yaşa Bağlı Maküla DejenerasyonundaKök Hücre Tedavisi, Gen Tedavisi ve Retinal İmplant

Uğur ACAR
Pages
149–154
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, very rapid advances have been developing related to the retinal prosthesis implantation which is performed to regain their functional vision in end stage ARMD patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nowadays there is no treatment option except antioxidant support which decelerates the progresion of dry type age related macular degeneration (ARMD) which is one of the most common reasons of the legal blindness in elderly people.
📊
Key Findings & Data:Promising outcomes have been obtained with stem cell treatment and gene therapy in dry type ARMD in the recent studies which are done in the light of the advanced bioengineering developments.
💡
Conclusion & Impact:In addition, very rapid advances have been developing related to the retinal prosthesis implantation which is performed to regain their functional vision in end stage ARMD patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nowadays there is no treatment option except antioxidant support which decelerates the progresion of dry type age related macular degeneration (ARMD) which is one of the most common reasons of the legal blindness in elderly people. Promising outcomes have been obtained with stem cell treatment and gene therapy in dry type ARMD in the recent studies which are done in the light of the advanced bioengineering developments. In addition, very rapid advances have been developing related to the retinal prosthesis implantation which is performed to regain their functional vision in end stage ARMD patients

Özet

İleri yaş nüfusunda yasal körlüklerin en sık sebeplerinden biri olan kuru tip yaşa bağlı maküla dejenerasyonu (YBMD) hastaları için, günümüzde hastalık progresyonunu yavaşlatan antioksidan desteği dışında tedavi seçeneği bulunmamaktadır. Biyomühendislik alanında yaşanan gelişmeler ışığında son dönemde yapılan çalışmalarda kuru tip YBMD'de kök hücre tedavisi ve gen tedavisi ile umut verici sonuçlar elde edilmiştir. Ayrıca son dönem YBMD hastalarının fonksiyonel görmelerini tekrar kazanmaları için uygulanan retinal protez implantasyonu ile ilgili çok hızlı ilerlemeler yaşanmaktadır

🔖

Cite This Article

ACAR, U. (2017). Gene therapy, Stem Cell Treatment and Retinal Implant in Dry-Form (Non-Neovascular) Age Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 2, 149–154. https://ajindex.com/articles/197475

References (15)

  1. Akkoyun İ. Yaşa bağlı maküla dejenerasyonu sınıflandırma ve patogenez. Turk J Ophthalmol. 2014;44:476-80
  2. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640-2
  3. Age Related Eye Disease Study Research Group: Risk factors associated with age-related macular degeneration. A case-control study in the agerelated eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224-32
  4. Uçar Çömlekoğlu D, Tigrel G. Kuru tip yaşa bağlı maküla dejenerasyonunda ilerleme engellenebilir mi? Yeni tedavi yöntemleri. Turkiye Klinikleri J Ophthalmol-Special Topics 2015;8(1):49-52
  5. Wei CX, Sun A, Yu Y, Liu Q, Tan YQ, Tachibana I, et al. Challenges in the development of therapy for dry age-related macular degeneration. Adv Exp Med Biol. 2016;854:103-9
  6. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-16
  7. Ramsden CM, Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal regeneration: past, present and future. Development 2013:140(12):2576-85
  8. Loeffler M, Roeder I. Tissue stem cells: definition, plasticity, heterogeneity, self-organization and models--a conceptual approach. Cells Tissues Organs 2002;171(1):8-26
  9. Özge G, Sobaci G. Retinada kök hücre nakli. Ret-Vit 2010;18:Özel Sayı:4- 8
  10. Acar U, Sobacı G. Yakın gelecek ne vaat ediyor?: Biyoteknoloji. Turkiye Klinikleri J Ophthalmol-Special Topics 2015;8(1):125-31
  11. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet. 1997;349(9057):990-3
  12. Menzel-Severing J, Kruse FE, Schlötzer-Schrehardt U. Stem cell-based therapy for corneal epithelial reconstruction: present and future. Can J Ophthalmol. 2013;48(1):13-21
  13. Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol 2013;6(5):565- 79
  14. Acar U, Beyazyıldız E, Pınarlı FA, Çankaya AB, Özdemir O, Özgermen S. Homing and migration ability of limbal mesenchymal stem cells on corneal injury model. Niche 2013;2(2):18-21
  15. Kaplan HJ, Tezel TH, Berger AS, Del Priore LV. Retinal transplantation. In: Streilein JW, ed. Immune resp